Incyte Corp(INCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 16.06 | EPS (ttm) | 7.85 | Insider Own | 0.91% | Shs Outstand | 201.0M | Perf Week | 0.82% |
| Market Cap | 25.55B | Forward P/E | 14.75 | EPS next Y | 127.05% | Insider Trans | -9.18% | Shs Float | 200.8M | Perf Month | 3.69% |
| Enterprise Value | 21.05B | PEG | 1.45 | EPS next Q | -2.83 | Inst Own | 103.05% | Short Float | 4.67% | Perf Quarter | 22.09% |
| Income | 1.61B | P/S | 4.39 | EPS this Y | -44.67% | Inst Trans | -1.21% | Short Ratio | 5.34 | Perf Half Y | 31.25% |
| Sales | 5.82B | P/B | 3.99 | EPS next 5Y | 10.16% | ROA | 23.55% | Short Interest | 9.39M | Perf YTD | 27.6% |
| Book/sh | 31.57 | P/C | 5.63 | EPS past 3/5Y | 61.53% - | ROE | 30.67% | 52W High | -4.95% ($132.60) | Perf Year | 47.23% |
| Cash/sh | 22.38 | P/FCF | 13.3 | Sales past 3/5Y | 14.84% 14.03% | ROIC | 25.3% | 52W Low | 55.42% ($81.09) | Perf 3Y | 96.98% |
| Dividend Est. | - | EV/EBITDA | 10.86 | EPS Y/Y TTM | 80.66% | Gross Margin | 91.42% | Volatility(W/M) | 2.62% 2.45% | Perf 5Y | 73.38% |
| Dividend TTM | - | EV/Sales | 3.62 | Sales Y/Y TTM | 26.93% | Oper. Margin | 31.61% | ATR (14) | 3.52 | Perf 10Y | 59.27% |
| Dividend Ex-Date | - | Quick Ratio | 4.51 | EPS Q/Q | 38.02% | Profit Margin | 27.71% | RSI (14) | 54.13 | Recom | 2.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.59 | Sales Q/Q | 37.72% | SMA20 | 0.34% ($125.6) | Beta | 0.74 | Target Price | $128.91 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/28 | SMA50 | 3.94% ($121.25) | Rel Volume | 0.72 | Prev Close | $124.4 |
| Employees | 2844 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 40.72% 11.31% | SMA200 | 20.09% ($104.95) | Avg Volume(3M) | 1.76M | Price | $126.03 |
| IPO | 1993/11/4 | Option/Short | Yes/Yes | Trades | 21555 | Volume | 1,271,979 | Change | 1.31% |
Company
INCY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A biotech company that develops and sells innovative new drugs in the fields of hematologic cancers, oncology, and skin diseases. Its key product is Jakafi (ruxolitinib), a treatment for myelofibrosis, along with Opzelura, a topical treatment for skin diseases, and a pipeline spanning oncology and immunology. It is a representative biotech company with its own drug discovery and development capabilities.
Over the past 1 year, on the higher side
5% below its 1-year high.
INCY makes money exceptionally well
31.61% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -44.7% this year.
Tap to view numbers
The price looks about right
Trading at 16.1 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +97.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 103.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.05%
BRNY 0.04%
IDNA 0.04%
QFRD 0.03%
FBT 0.03%It ranks #4 in the industry
Based on market cap of $26B.
INCY $26B PER 16.1
VRTX $132B PER 30.3
REGN $83B PER 20.0
ARGX $63B PER 38.2
FAQ
What kind of company is INCY?
INCY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INCY?
The market cap of INCY is approximately $25.5B, ranking 519 within its sector.
What is the P/E ratio of INCY?
INCY has a P/E ratio of approximately 16.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INCY?
INCY has recorded a 52-week high of $132.60 and a low of $81.09.
